Profil de l'entreprise pour 2seventy bio, Inc. - Common Stock Action
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Analyse IA de 2seventy bio, Inc. - Common Stock
Cliquez sur l’une des analyses ci-dessous pour obtenir des informations instantanées de l’IA via finAgent
Dernières analyses d’IA sur 2seventy bio, Inc. - Common Stock
Aucun fil IA disponible pour cette entreprise pour le moment.